๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Locally Advanced or Metastatic Breast Cancer
Clinical trial register · China

Locally Advanced or Metastatic Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Beijing 3 Fuzhou 3 Shanghai 3 Bengbu 2
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou6 Beijing3 Fuzhou3 Shanghai3 Bengbu2
All 25 locations
Target enrolment
to

Locally Advanced or Metastatic Breast Cancer trials in China

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
NCT07354022Locally Advanced or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3
912
Beijing
2026-05-05
Recruiting
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
NCT07461454Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
376
Shanghai
2026-03-17
Not yet open
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT07235618Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 2
50
Guangzhou
2026-01-05
Active, closed
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Recruiting
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
NCT06439771Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
180
Shanghai
2024-04-23
Recruiting
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05860465Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
254
Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing
2023-09-08
Recruiting
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
NCT05744687Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
374
Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan
2023-04-24
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Not yet open
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05172518Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/locally-advanced-or-metastatic-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition Locally Advanced or Metastatic Breast Cancer.

How many Locally Advanced or Metastatic Breast Cancer trials are recruiting in China?

7 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Locally Advanced or Metastatic Breast Cancer), 11 studies
PhaseStudiesRecruitingShare
Phase 36354.5%
Phase 22118.2%
Phase 2/32218.2%
Not applicable119.1%

Most active sponsors

Lead sponsors with the most studies (Locally Advanced or Metastatic Breast Cancer)
Lead sponsorStudiesRecruiting
Sun Yat-sen University31
MediLink Therapeutics (Suzhou) Co., Ltd.22
Shanghai Pharmaceuticals Holding Co., Ltd22
Fudan University11
Hoffmann-La Roche10
Jiangsu Simcere Pharmaceutical Co., Ltd.10
Shandong Suncadia Medicine Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.